ESMO 2018 (Munich): The World’s Premier Congress in Medical Oncology
Elaborating the subject of oncolytic viruses: research continues to provide deeper insights on the potential of cancer virotherapy.
Read More
The Regional Administrative Court Concludes: The Manufacturer of Rigvir has not Committed Unfair Commercial Practices
The informing of industry professionals on the use of Rigvir for other diagnoses (“off-label”) is legally acceptable.
Read More
The Advent of Oncolytic Virotherapy in Oncology: The Rigvir® Story
Numerous viruses have been tested in clinical trials and three are approved. Our virus was the first.
Full Publication
Pioneers of Oncolytic Virotherapy with Biotechnological Focus
We are committed to prove, that the cancer treatment can be safe, effective and harmless.
Our Company
We are Excited About the Future and Proud of Our Past
In the 1960s with the efforts of professor Aina Muceniece the focus points in the perception of cancer started to shift.
Our History
We Believe in the Good Virus
We invest in biomanufacturing and we focus on growing our portfolio of virotherapy medicines that meet the real needs of patients.
Products
From Virotherapy Focus to Vision of Life Science
Innovations in biotechnological cancer treatments are the key concepts for improving the health quality of global population.
Focus Areas
Diversified Social Commitment is Part of Our Business Strategy
One of our areas of partnership interest is art. We invite art professionals and amateurs, oncological patients to create new artistic works to inspire the fight with cancer.
For Social Partners